Details

Autor(en) / Beteiligte

• Tokunaga, Takayuki
• Tateyama, Masakuni
• Kondo, Yasuteru
• Miuma, Satoshi
• Miyase, Shiho
• Tanaka, Kentaro
• Narahara, Satoshi
• Inada, Hiroki
• Kurano, Sotaro
• Yoshimaru, Yoko
• Nagaoka, Katsuya
• Watanabe, Takehisa
• Setoyama, Hiroko
• Fukubayashi, Kotaro
• Tanaka, Motohiko
• Tanaka, Yasuhito

Titel

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma

Ist Teil von

• Cancers, 2023-03, Vol.15 (5), p.1568

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• We retrospectively evaluated the impact of therapeutic modifications of atezolizumab (Atezo) plus bevacizumab (Bev) therapy (Atezo/Bev), including the interruption or discontinuation of both Atezo and Bev, and the reduction or discontinuation of Bev, on the outcome of patients with unresectable hepatocellular carcinoma (uHCC) (median observation period: 9.40 months). One hundred uHCC from five hospitals were included. Therapeutic modifications without discontinuation of both Atezo and Bev ( = 46) were associated with favorable overall survival (median not reached; hazard ratio (HR): 0.23) and time to progression (median: 10.00 months; HR: 0.23) with no therapeutic modification defined as the reference. In contrast, the discontinuation of both Atezo and Bev without other therapeutic modifications ( = 20) was associated with unfavorable overall survival (median: 9.63 months; HR: 2.72) and time to progression (median: 2.53 months; HR: 2.78). Patients with modified albumin-bilirubin grade 2b liver function ( = 43) or immune-related adverse events (irAEs) ( = 31) discontinued both Atezo and Bev without other therapeutic modifications more frequently (30.2% and 35.5%, respectively) than those with modified albumin-bilirubin grade 1 (10.2%) and without irAEs (13.0%). Patients with objective response ( = 48) experienced irAEs more frequently ( = 21) than those without ( = 10) ( = 0.027). Avoiding the discontinuation of both Atezo and Bev without other therapeutic modifications may be the optimal management of uHCC.